Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
The appropriate response is hydrogen bonds. Fever is an adjust of gainful and destructive impacts. High fevers can have a tendency to skew the adjust toward the destructive.
The reality of the matter is that protein optional structure (generally hydrogen bonds) start to denature when moving toward 41 degC (106 degF), however energy likewise change. Energy is a quite major ordeal, even a little temperature move can altogether affect the speed of a response or connection.
<span>Living things are made of cells.Living things obtain and use energy.Living things grow and develop.Living things reproduce.Living things respond to their environment.<span>Living things adapt to their environment.</span></span>
In a centrifuged sample of blood the PLATELETS should not be in the plasma portion of the sample. Centrifugation of blood samples separates the blood to its constituents on the basis of their densities. Platelets will be found on the middle region of the separation and not in the upper region where plasma is .
Answer:
They use a gene modification technique called CRIPSR-CAS9. The pigs have been given a gene that allows them to better regulate their own body temperature, whereby they burn fat, or at which animals consume their own fat.
Explanation:
British and Chinese scientists explained that they conducted the study by adding a mouse version of the UCP1 gene used for porcine embryos, which is used to regulate body temperature characteristic of most mammals, but not ordinary pigs.
It is problematic for pigs to maintain a stable body temperature, and this is especially complicated in pigs that are cold in the winter months because they have not been able to "store" fat.
Inserting the UCP2 gene could solve this problem.
